Imatinib buys time for brain after stroke.
Rieckmann
Peter
P
D000818:Animals; D001549:Benzamides; D001812:Blood-Brain Barrier / Q000473:pathology; D001921:Brain / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology*; D002545:Brain Ischemia / Q000188:drug therapy; D002536:Cerebral Arteries / Q000378:metabolism; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000068877:Imatinib Mesylate; D008222:Lymphokines / Q000037:antagonists & inhibitors*; D051379:Mice; D008954:Models, Biological; D010879:Piperazines / Q000627:therapeutic use*; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000627:therapeutic use*; D011859:Radiography; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects; D020521:Stroke / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013997:Time Factors
D001549:Benzamides; D008222:Lymphokines; D010879:Piperazines; D010982:Platelet-Derived Growth Factor; D011743:Pyrimidines; C411423:platelet-derived growth factor C; D000068877:Imatinib Mesylate; D020796:Receptor, Platelet-Derived Growth Factor alpha